Oppenheimer & Co. Inc. Has $17.55 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Oppenheimer & Co. Inc. lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,376 shares of the company's stock after selling 16,972 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Novo Nordisk A/S were worth $17,548,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Advisor OS LLC raised its position in shares of Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company's stock worth $1,994,000 after purchasing an additional 82 shares during the period. Cascade Financial Partners LLC grew its holdings in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company's stock worth $543,000 after buying an additional 84 shares in the last quarter. Novare Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock worth $325,000 after buying an additional 85 shares in the last quarter. AA Financial Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 3.2% during the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company's stock worth $400,000 after buying an additional 86 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after buying an additional 86 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on NVO shares. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $0.14 during mid-day trading on Wednesday, hitting $106.93. 3,156,511 shares of the stock were exchanged, compared to its average volume of 4,440,904. The stock has a market capitalization of $479.83 billion, a price-to-earnings ratio of 34.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42. The firm's 50-day simple moving average is $120.23 and its 200 day simple moving average is $130.08. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.